MétaCan
Menu
Back to cohort
Record W4231626700 · doi:10.1002/hep.27461

Parallel 12: Hepatitis C: New Agents -Part 1

2014· article· en· W4231626700 on OpenAlexfundno aff

Bibliographic record

VenueHepatology · 2014
Typearticle
Languageen
FieldMedicine
TopicHepatitis C virus research
Canadian institutionsnot available
FundersNIH Clinical CenterNational Institutes of HealthUniversity of TorontoNational Center for Global Health and MedicineNational Institute of Allergy and Infectious DiseasesJohns Hopkins UniversityFrederick National Laboratory for Cancer ResearchUniversity of PennsylvaniaGilead Sciences
KeywordsVirologyHepatitis CMedicineHepatitis

Abstract

fetched live from OpenAlex

Hepatitis C is the commonest cause of hepatocellular cancer (HCC) in the US and the incidence is expected to increase further as the HCV population ages and develops more cirrhosis.Management of HCC is very heterogenous with multiple non-surgical and surgical options.The true cost of care of the HCV patient with HCC is unknown.AIMS: To evaluate the total direct health care costs of different approaches to HCC care in HCV patients in a major referral and transplant center.METH-ODS: 101 patients were randomly selected by computer from a list of all HCC patients with HCV between 2003 and 2013.All patients were biopsy-proven HCC or met UNOS OPTN criteria.Patients were categorized by the primary treatment modality of TACE, Cyberknife radiotherapy, radiofrequency abalation (RFA), chemotherapy or resection.Patients could have multiple treatment modalities and also go on to liver transplant, which is considered as a separate modality for cost determination.The direct cost includes the cost of the procedure, imaging, hospitalizations and all subsequent care of the HCC patient until either death or transplant including cost of HCV treatment and immunosuppression post-transplant.Costs were derived from the Medicare fee schedule abstracted from the HCUP NIS sample 2011.Medication costs used were wholesale acquisition costs (Redbook 2014).RESULTS: 101 patients, 82 male mean age 59years (range 49-82) were included.All had HCV cirrhosis at diagnosis with a median CTP score of 7 ( range 5-11) and a median MELD of 8. Genotype 1 (74%) and genotype 3 (16%) were predominant.31 patients were HCV treatment naïve, 65 treatment failures and 4 had had a prior SVR.Majority of HCC were detected through cross-sectional radiological screening programs.Liver staging using the Barcelona score was A1 20%; A2 18%; A3 16% and A4 27%; B 12% and C 7%.Tumor size was mean 2.8cms with a range from 1 -14cms.Mean follow up was 32 months with a range from 4 -118 and 37 patients have died.Initial primary treatment modalities were RFA 53%; TACE 26%; Cyberknife 10%, resection 8% and chemotherapy 2%.43 patients went on to liver transplantation.Calculated overall cost of HCC care for this group of patients was $22,030,108 for a mean cost per patient of $218,120.The 43 patients who underwent transplant accounted for $17,025,037 of the overall costs at $395,000 per transplanted patient compared to $5,817,300 for the non transplant patients for a mean cost of $100,299 per patient.CONCLUSIONS: Pharmaco-economic studies of HCV treatment need to model real life estimations of true direct cost of HCC care.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: none
Teacher disagreement score0.152
Threshold uncertainty score0.509

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0030.002
Science and technology studies0.0000.000
Scholarly communication0.0020.002
Open science0.0010.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.1520.095

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.063
GPT teacher head0.340
Teacher spread0.276 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueHepatologySame topicHepatitis C virus researchFrench-language works237,207